Article Figures & Data
Figures
- Figure 1a.
Multi-focal, peripheral, rounded ground glass opacities seen on the right upper and adjacent lower lobes (arrows) are commonly reported features of COVID-19.
- Figure 1b.
The multi-focal subsegmental consolidations, with ill-defined ground-glass opacities, of the posterior lower lobes (arrows), are nonspecific.
Tables
Lab Day 0 Day 1 Day 2 Day 3 WBC × 103/µL 5.5 5.2 5.5 4.4 Neutrophils abs, 103/µL 4.1 4.1 3.8 2.6 Neutrophil, % 74.4 78.1 68.7 59.3 Lymphocyte abs, 103/µL 0.8 0.6 1.0 1.1 Lymphocyte, % 15.1 11.6 18.7 25 Platelet, 103/µL 127 122 155 182 C-reactive protein, mg/dL 8.15 9.01 5.05 Erythrocyte sedimentation rate, mm/hr 55 68 74 Ferritin, ng/mL 1698 1723 1880 D-dimer, µg/mL 0.70 1.11 LDH, U/L 321 321 316 Albumin, g/dL 4.1 4.1 3.6 3.8 Prothrombin time, s 14.0 Aspartate aminotransferase, U/L 38 33 31 42 Alanine aminotransferase, U/L 31 30 32 53 Creatine kinase, U/L 46 50 51 49 Interluekin-6, pg/mL 55.6 High-sensitivity troponin, ng/L 6.4 6.8 6.1 WBC, white blood cells; LDH, lactate dehydrogenase.
Study Nation of Origin COVID-19 Comparison Groups Study Design Sample Size N Mo et al.4 China Refractory vs Non-refractory Retrospective cohort 155 Wu et al.6 China ARDS vs No ARDS Retrospective cohort 201 Zhou et al.7 China Non-survivor vs Survivor Retrospective cohort 191 Zhang et al.8 China Severe vs Non-severe COVID-19 Retrospective cohort 140 Du et al.9 China Non-survivor vs Survivor Prospective cohort 179 Li et al.10 China Non-survivor vs Survivor Retrospective cohort 102 ARDS, acute respiratory distress syndrome; vs, versus.
Co-Morbidities and Laboratory findings Non-Survivor vs Survivor7 Refractory vs Non-refractory disease4 ARDS vs No ARDS6 Severe vs Non-severe disease8 Non-Survivor vs Survivor10 Non-Survivor vs Survivor9 Hypertension 48% vs 23% No significant difference 27.4% vs 13.7% No significant difference No significant difference 61.9% vs 28.5% Diabetes mellitus 31% vs 14% 12% vs 3% 19% vs 5.1% No significant difference No significant difference No significant difference Coronary artery or cardiovascular disease 24% vs 1% 14% vs 0% No significant difference No significant difference 13% vs 2% 57.1 vs 10.8% Respiratory disease or COPD 7% vs 1% NA NA No significant difference No significant difference NA Leukocytes, 109/L 9.8 vs 5.2 No significant difference 8.32 vs 5.02 109/mL** 5.3 vs 4.5 9.1 vs 5.5 8.9 vs 5.1 Lymphocytes, 109/L 0.6 versus 1.1 No significant difference 0.67 vs 1.08 109/mL** 0.7 vs 0.8 0.5 vs 0.9 0.7 vs 0.8 Platelets, 109/L 165.5 vs 220 159 vs 179 178 vs 187 × 109/mL** NA 113 vs 206.5 NA ESR NA No significant difference No significant difference NA NA NA CRP, mg/L NA 46 vs 23 83 vs 234 47.6 vs 28.7 78.7 vs 25.4 86.4 vs 36 LDH, U/L 521 vs 253.5 293 vs 241 396 vs 257 NA 569 vs 272 NA Ferritin 1435.3 vs 503.2 µg/L NA 1029 vs 457 ng/mL NA NA NA D-dimer, µg/mL 5.2 vs 0.6 No significant difference 1.16 vs 0.52 0.4 vs 0.2 2.1 vs 0.7 1.1 vs 0.5 PT, seconds 12.1 vs 11.4 NA 11.7 vs 10.6 NA 14.9 vs 14.1 No significant difference Interleukin-6, pg/mL 11.0 vs 6.3 NA 7.39 vs 6.29 NA 48.4 vs 4.2 NA Procalcitonin, ng/mL 0.1 vs 0.1 No significant difference No significant difference 0.1 vs 0.05 0.19 vs 0.05 0.1 vs 0.1 ARDS, acute respiratory distress syndrome; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase; PT, prothrombin time; NA, not addressed; vs, versus; COPD, chronic obstructive pulmonary disease.
*Clinical significance was defined by P < .05. Percentages are reported as prevalence of the co-morbidity within each respective group. Laboratory findings were specified as values on admission for all 5 retrospective cohort studies.
** We believe 109/mL units are reflected as an error and should reflect 109/L. We have contacted the referenced journal to inquire.
